Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Stomach Neoplasms 1 Peritoneal Neoplasms 1 Neoplasms by Site 1 Liver Neoplasms 1 Liver Diseases 1 Hemangiosarcoma 1 Digestive System Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Hepatocellular 1

Interventions

Paclitaxel 7 Doxorubicin 5 pembrolizumab 4 pazopanib 4 Gemcitabine 4 Bevacizumab 4 durvalumab 3 Radiotherapy 3 Propranolol 3 Docetaxel 3 regorafenib 2 cemiplimab 2 Surveys and Questionnaires 2 Sunitinib 2 Standard of Care 2 Nivolumab 2 Ifosfamide 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 zanidatamab 1 veliparib 1 tucatinib 1 trilaciclib 1 tremelimumab 1 trebananib 1 trastuzumab duocarmazine 1 talimogene laherparepvec 1 talazoparib 1 spartalizumab 1 sintilimab 1 selinexor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Hemangiosarcoma × genexol-PM × Clear all

NCT03512834 2018-07-11

ASAP

Dong-A University Hospital

Phase 2 Unknown

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡